HC Wainwright Has Bearish Forecast for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at HC Wainwright dropped their FY2025 EPS estimates for Harmony Biosciences in a report issued on Wednesday, August 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn $3.55 per share for the year, down from their prior forecast of $3.83. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q1 2026 earnings at $0.75 EPS, FY2026 earnings at $4.08 EPS and FY2027 earnings at $5.00 EPS.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday. Truist Financial started coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a “buy” rating and a $48.00 price target for the company. Oppenheimer started coverage on shares of Harmony Biosciences in a report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $55.00 price target (up previously from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Harmony Biosciences Trading Up 1.8%

NASDAQ:HRMY opened at $34.80 on Monday. Harmony Biosciences has a 52 week low of $26.47 and a 52 week high of $41.61. The firm has a 50 day moving average of $34.15 and a 200 day moving average of $33.75. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of 11.23, a PEG ratio of 0.40 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The firm had revenue of $200.49 million for the quarter, compared to analysts’ expectations of $204.37 million. During the same period in the previous year, the company earned $1.05 EPS. The company’s revenue was up 16.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HRMY. Deep Track Capital LP purchased a new position in shares of Harmony Biosciences during the fourth quarter worth $49,894,000. Boston Partners purchased a new position in shares of Harmony Biosciences during the second quarter worth $19,398,000. Marshall Wace LLP raised its holdings in shares of Harmony Biosciences by 165.2% during the fourth quarter. Marshall Wace LLP now owns 929,744 shares of the company’s stock worth $31,992,000 after purchasing an additional 579,103 shares during the last quarter. New Vernon Capital Holdings II LLC raised its holdings in shares of Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock worth $16,211,000 after purchasing an additional 473,708 shares during the last quarter. Finally, LSV Asset Management raised its holdings in shares of Harmony Biosciences by 24.6% during the second quarter. LSV Asset Management now owns 1,488,502 shares of the company’s stock worth $47,037,000 after purchasing an additional 293,541 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.